A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Lilly, M
Kuriakose, P
Turturro, F
Berdeja, J
Kerr, R
Surendranathan, A
Black, J
Frankel, A
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Louisiana State Univ, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA
[4] SW Reg Canc Ctr, Austin, TX USA
[5] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[6] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：597S / 597S
页数：1
相关论文
共 50 条
  • [31] Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial
    Mauro, Francesca R.
    Carella, Angelo M.
    Molica, Stefano
    Paoloni, Francesca
    Liberati, Anna M.
    Zaja, Francesco
    Belsito, Valeria
    Cortellezzi, Agostino
    Rizzi, Rita
    Tosi, Patrizia
    Spriano, Mauro
    Ferretti, Antonietta
    Nanni, Mauro
    Marinelli, Marilisa
    De Propris, Maria S.
    Orlando, Sonia M.
    Vignetti, Marco
    Cuneo, Antonio
    Guarini, Anna R.
    Foa, Robin
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1640 - 1647
  • [32] A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211
    Byrd, JC
    Peterson, B
    Piro, L
    Saven, A
    Vardiman, JW
    Larson, RA
    Schiffer, C
    LEUKEMIA, 2003, 17 (02) : 323 - 327
  • [33] A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211
    J C Byrd
    B Peterson
    L Piro
    A Saven
    J W Vardiman
    R A Larson
    C Schiffer
    Leukemia, 2003, 17 : 323 - 327
  • [34] Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study.
    Gribben, J
    Stephans, K
    Marshal, B
    BLOOD, 2005, 106 (11) : 343B - 343B
  • [35] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [36] A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
    Flowers, Christopher R.
    Brown, Jennifer R.
    Rosenthal, Hilary
    Stock, Wendy
    Katzen, Harvey I.
    Cohen, Jonathon B.
    Sinha, Rajni
    Lakhanpal, Shailendra
    Leis, Jose F.
    Waller, Edmund K.
    Jaye, David L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 694 - 698
  • [37] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [38] Fludarabine as single therapy for advanced stage of refractory chronic lymphocytic leukemia.
    Giraldo, P
    Palomera, L
    Mayayo, P
    Moneva, JJ
    Diego, P
    Pardo, M
    Rabasa, P
    Rubio-Félix, D
    BLOOD, 1998, 92 (10) : 276B - 276B
  • [39] Proteins that influence apoptosis in B-cell chronic lymphocytic leukemia.
    Filip, A
    Marzec, B
    Koczkodaj, D
    Kubiatowski, T
    Grabek-Gawlowicz, M
    Wojcierowski, J
    BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY, 2002, : 3 - 8
  • [40] Bendamustin in induction of apoptosis in B-cell chronic lymphocytic leukemia.
    Schwaenen, C
    Karakas, T
    Brückle, E
    Hecker, T
    Schmitt, M
    Bergmann, L
    BLOOD, 1999, 94 (10) : 196B - 196B
12345